Evidence map›Paper›PMID 28588723›Full record

ArticleOncology letters2017

Analysis of the correlation between the expression of miR-655 and esophageal cancer prognosis.

Peng Chang, Xiangjun Wang, Ya Zhou, Yulong Hou

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. [MiR-665 Promotes the Biological Behavior of Small Cell Lung Cancer by Targeting LLGL1].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2020
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Peng ChangDepartment of Thoracic and Cardiac Surgery, Xuzhou Cancer Hospital, Xuzhou, Jiangsu 221005, P.R. China.
Xiangjun WangDepartment of Thoracic and Cardiac Surgery, Xuzhou Cancer Hospital, Xuzhou, Jiangsu 221005, P.R. China.
Ya ZhouDepartment of Thoracic and Cardiac Surgery, Xuzhou Cancer Hospital, Xuzhou, Jiangsu 221005, P.R. China.
Yulong HouDepartment of Thoracic and Cardiac Surgery, Xuzhou Cancer Hospital, Xuzhou, Jiangsu 221005, P.R. China.
Jiangsu University · CNXuzhou Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The correlation between the expression level of microRNA (miR)-655 in esophageal cancer with proliferation, invasion and prognosis was investigated. Reverse transcription-quantitative polymerase chain reaction technique was used to detect the expression level of miR-655 in esophageal cancer cell lines KYSE410 and EC9706, tumor tissues and normal cancer-adjacent tissues of 63 cases of patients with esophageal squamous cell carcinoma (ESCC). The expression of miR-655 was upregulated in ESCC cells through the transfection of miR-655 mimics, and the influence of miR-655 on proliferation and invasion ability of ESCC cells was observed. Combined with the clinical data, the correlation between the expression of miR-655 and the prognosis of esophageal cancer was analyzed. The expression of miR-655 was downregulated in 2 ESCC cell lines and 73.02% of ESCC tissues. The results showed that the increased expression of miR-655 via transfection of mimics inhibited the proliferation and invasion ability of ESCC cells. Combined with clinical data analysis, it was found that the low-expression of miR-655 was related to poorer progression-free survival. In conclusion, the high-expression of miR-655 can inhibit the proliferation and invasion of ESCC, and plays a negative regulation role in the prognosis process of tumor patients. The targeted regulation of miR-655 can be used as a new treatment method of ESCC.

Indexed as

esophageal squamous cell carcinomametastasismiR-655prognosisproliferation

Identifiers

PMID28588723
PMCPMC5452899
OpenAlexW2606841856

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.